Becton, Dickinson and Company (BD) has formed a strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA) in the US to establish new manufacturing lines for injection devices.
BARDA is part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
The company’s additional manufacturing lines will provide the US Government with priority access to huge volumes of syringes and needles to support its ongoing and future pandemic vaccination efforts.
As part of the partnership, BARDA will invest an estimated $42m into a $70m capital project to expand BD’s operations and manufacturing capacity in Nebraska within 12 months.
Once completed, BARDA will have priority access to injection devices from the new manufacturing lines to support mass vaccination efforts for Covid-19 and future pandemics in the US.
In addition, BD also finalised an initial pandemic order for 50 million needles and syringes to be delivered by the end of this year to support the country’s Covid-19 vaccination effort.
The order will be fulfilled using the company’s existing manufacturing capacity. BD noted the initial order will not affect the ability to fulfil existing customer requirements for needles and syringes.
BD Medication Delivery Solutions president Rick Byrd said: “BD’s commitment to produce 50 million vaccine injection devices by the end of this year to support the US Covid-19 vaccination campaign is the latest effort in the company’s multifaceted global response to this virus, and the new, strategic public-private partnership will help ensure the US is prepared for future pandemic vaccination efforts.
“We are extremely proud of our talented and dedicated workforce in Nebraska and our longstanding partnership with the state, and we look forward to building on our strong presence and track record in Nebraska as we move forward.”
Meanwhile, BD is also working to expand access to diagnostic testing and support treatment of Covid-19 patients in the US.
The company has supplied approximately 48 million swabs for flu and Covid-19 testing and over 2.85 million Covid-19 rapid molecular diagnostic tests on the BD MAX System globally.